Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from NKGen Biotech ( (NKGN) ).
On May 15, 2026, NKGen Biotech and its subsidiary NKGen Operating Biotech entered a second amendment to their secured convertible loan agreement with AlpineBrook Capital GP I, securing an additional $412,500 loan, of which $375,000 represents net proceeds. The new secured convertible note and associated warrant are convertible or exercisable into common stock at $0.08 per share, and the number of consideration shares to be issued to the lender was increased to 12,147,280 shares, to be delivered over 25 months.
Also on May 15, 2026, NKGen issued an additional common stock purchase warrant tied to the new note, with a ten-year term, cashless exercise features, a 9.99% beneficial ownership cap and anti-dilution protections. The company and key shareholders entered a voting agreement to support an increase in authorized common shares sufficient to cover all consideration shares and potential issuances from the convertible notes and warrants, with shareholder approval required within two months of the loan closing or before the next financing.
The securities underlying the new loan, warrants and consideration shares were agreed to be issued without registration under the Securities Act of 1933, relying on private offering exemptions such as Section 4(a)(2), Regulation D and Regulation S. These arrangements further entrench AlpineBrook as a significant financing partner while positioning NKGen to access additional equity capital through future conversions and warrant exercises, albeit with potential dilution for existing shareholders.
More about NKGen Biotech
NKGen Biotech, Inc. is a biotechnology company focused on developing cell-based therapies, including natural killer (NK) cell technologies. The company operates through its wholly owned subsidiary NKGen Operating Biotech, Inc. and accesses capital markets and structured financing to support its clinical and operational needs.
Average Trading Volume: 2,635
Technical Sentiment Signal: Sell
Current Market Cap: $7.84M
Find detailed analytics on NKGN stock on TipRanks’ Stock Analysis page.